Biotech entity
pharma is the sole category represented across all 1 tracked stories. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Nektar Therapeutics, all published on March 22, 2026.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Nektar Therapeutics, all published on March 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nektar Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Litigation Filed
Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
Partnership Termination
BMS and Nektar officially end their global clinical development collaboration.
Phase 3 Failure
Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
BMS Partnership
Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Nektar Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
